Ankur Jindal, MD
Endocrinology, Diabetes & Metabolism · Huntsville, ALNPI 1003014705
Payments from drug & device makers
Across 421 payments — averaging $15.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Dexcom, Inc.$708
- Sanofi-aventis U.S. LLC$546
- Abbott$500
- Lilly USA, LLC$370
- AbbVie$292
- plus $3K from 32 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 116 | $1,237 |
| Dexcom, Inc. | 48 | $708 |
| Sanofi-aventis U.S. LLC | 31 | $546 |
| Abbott | 32 | $500 |
| Lilly USA, LLC | 25 | $370 |
| AbbVie | 18 | $292 |
| Xeris Pharmaceuticals, Inc. | 15 | $285 |
| Medtronic(2 entities) | 16 | $283 |
| Tandem Diabetes Care, Inc. | 15 | $256 |
| AstraZeneca | 13 | $219 |
| BETA Bionics, Inc. | 6 | $200 |
| Insulet Corporation | 2 | $147 |
| Johnson & Johnson | 9 | $127 |
| Corcept Therapeutics | 7 | $120 |
| Boehringer Ingelheim | 7 | $114 |
| Amgen(2 entities) | 7 | $110 |
| Bayer | 4 | $81 |
| Merck | 5 | $77 |
| Amryt Pharma Holdings Ltd | 3 | $66 |
| Shire North American Group Inc | 3 | $61 |
| IBSA Pharma Inc. | 4 | $57 |
| Kyowa Kirin, Inc. | 3 | $54 |
| GRT US Holding, Inc. | 3 | $47 |
| Zealand Pharma US, Inc. | 3 | $45 |
| Ultragenyx Pharmaceutical Inc. | 2 | $44 |
| Chiesi USA, Inc. | 2 | $37 |
| Recordati_rare_diseases_inc. | 2 | $34 |
| Ascendis Pharma Endocrinology Inc | 2 | $34 |
| Eisai Inc. | 2 | $34 |
| Mannkind Corporation | 2 | $32 |
| Pfizer | 2 | $31 |
| Madrigal Pharmaceuticals | 1 | $28 |
| Amneal Pharmaceuticals LLC | 2 | $28 |
| Senseonics, Incorporated | 4 | $23 |
| Amarin Pharma, Inc. | 2 | $23 |
| Novartis | 1 | $21 |
| Intra-sana Laboratories | 1 | $20 |
| Averitas Pharma Inc. | 1 | $16 |
How this compares
$6,407 in reported general payments places this provider in the 45th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.
See all endocrinology, diabetes & metabolism providers in Alabama →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other endocrinology, diabetes & metabolism in Huntsville
- Dwain WoodeHuntsville$78K
- Malapuram Vasudha ReddyHuntsville$6K
- Joshua TateHuntsville$5K
- Bobby JohnsonHuntsville$4K
- William GarveyBirmingham$3.8M
- Neil SchaffnerOpelika$642K
- Fernando OvalleBirmingham$516K
- Ralph TeagueBirmingham$487K
- Bantwal BaligaOpelika$483K
- Judson MenefeeFairhope$185K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.